Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

Clara De Simone; Francesca Perino; Giacomo Caldarola; Magda D'Agostino; Ketty Peris

doi:10.1177/0300060515593250

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

Clara De Simone^*, Francesca Perino, Giacomo Caldarola, Magda D'Agostino, Ketty Peris

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo in rivista

9 Citazioni (Scopus)

Abstract

Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.

Lingua originale	English
pagine (da-a)	67-71
Numero di pagine	5
Rivista	Journal of International Medical Research
Volume	44
DOI	https://doi.org/10.1177/0300060515593250
Stato di pubblicazione	Pubblicato - 2016

Keywords

Antitumour necrosis factor-α agents
Biochemistry
Biochemistry (medical)
Cell Biology
Medicine (all)
comorbidities
etanercept
psoriasis
psoriatic arthritis

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1177/0300060515593250

Altri file e collegamenti

Cita questo

@article{36736da159bf4e97bdc72769a0b81219,

title = "Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports",

abstract = "Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.",

keywords = "Antitumour necrosis factor-α agents, Biochemistry, Biochemistry (medical), Cell Biology, Medicine (all), comorbidities, etanercept, psoriasis, psoriatic arthritis, Antitumour necrosis factor-α agents, Biochemistry, Biochemistry (medical), Cell Biology, Medicine (all), comorbidities, etanercept, psoriasis, psoriatic arthritis",

author = "{De Simone}, Clara and Francesca Perino and Giacomo Caldarola and Magda D'Agostino and Ketty Peris",

year = "2016",

doi = "10.1177/0300060515593250",

language = "English",

volume = "44",

pages = "67--71",

journal = "Journal of International Medical Research",

issn = "0300-0605",

publisher = "Cambridge Medical Publications Limited:Wicker House High Street, Worthing West Sussex BN11 1DJ United Kingdom:011 44 1903 288247, EMAIL: [email protected], INTERNET: http://www.cambridge-medical.com, Fax: 011 44 1903 234862",

}

TY - JOUR

T1 - Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

AU - De Simone, Clara

AU - Perino, Francesca

AU - Caldarola, Giacomo

AU - D'Agostino, Magda

AU - Peris, Ketty

PY - 2016

Y1 - 2016

N2 - Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.

AB - Tumour necrosis factor (TNF)-α blocking agents have revolutionized the treatment of psoriasis and psoriatic arthritis. Concerns remain about increased susceptibility to infection and onset of malignancies, and the use of TNF-α agents in patients with HIV infection or undergoing immunosuppressant treatment is debated. We report cases of severe plaque psoriasis in a patient with HIV infection and in a liver transplant recipient who were successfully treated with etanercept, an anti-TNF-α agent, without notable side-effects.

KW - Antitumour necrosis factor-α agents

KW - Biochemistry

KW - Biochemistry (medical)

KW - Cell Biology

KW - Medicine (all)

KW - comorbidities

KW - etanercept

KW - psoriasis

KW - psoriatic arthritis

KW - Antitumour necrosis factor-α agents

KW - Biochemistry

KW - Biochemistry (medical)

KW - Cell Biology

KW - Medicine (all)

KW - comorbidities

KW - etanercept

KW - psoriasis

KW - psoriatic arthritis

UR - http://hdl.handle.net/10807/92635

UR - http://imr.sagepub.com/content/by/year

U2 - 10.1177/0300060515593250

DO - 10.1177/0300060515593250

M3 - Article

SN - 0300-0605

VL - 44

SP - 67

EP - 71

JO - Journal of International Medical Research

JF - Journal of International Medical Research

ER -

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo